baltimore conference logo
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD: Case 1

Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD

EP. 1: Shreyaskumar R. Patel, MD: Leiomyosarcoma Differing From Those Arising at Other Sites

December 21st 2015

EP. 2: Shreyaskumar R. Patel, MD: Standard of Care for Invasive, Unresectable Leiomyosarcoma

December 21st 2015

EP. 3: Shreyaskumar R. Patel, MD: Risk/Benefit Ratio of Using Ifosfamide in This Patient

December 21st 2015

EP. 4: Shreyaskumar R. Patel, MD: Additional Chemotherapy in This Patient

December 21st 2015

EP. 5: Shreyaskumar R. Patel, MD: Targeted Therapies Influencing Treatment Options

December 21st 2015

EP. 6: Shreyaskumar R. Patel, MD: Additional Options Available for Durable Response

December 21st 2015

EP. 7: Jonathan C. Trent, MD, PhD: Leiomyosarcoma Differing From Those Arising at Other Sites

December 21st 2015

EP. 8: Jonathan C. Trent, MD, PhD: Standard of Care for Invasive, Unresectable Leiomyosarcoma

December 21st 2015

EP. 9: Jonathan C. Trent, MD, PhD: Risk/Benefit Ratio of Using Ifosfamide in This Patient

December 21st 2015

EP. 10: Jonathan C. Trent, MD, PhD: Additional Chemotherapy in This Patient

December 21st 2015